학술논문
Genome-wide association study of prostate-specific antigen levels in 392,522 men identifies new loci and improves cross-ancestry prediction
Document Type
Author
Hoffmann, Thomas J; Graff, Rebecca E; Madduri, Ravi K; Rodriguez, Alex A; Cario, Clint L; Feng, Karen; Jiang, Yu; Wang, Anqi; Klein, Robert J; Pierce, Brandon L; Eggener, Scott; Tong, Lin; Blot, William; Long, Jirong; Rebbeck, Timothy; Lachance, Joseph; Andrews, Caroline; Adebiyi, Akindele O; Adusei, Ben; Aisuodionoe-Shadrach, Oseremen I; Fernandez, Pedro W; Jalloh, Mohamed; Janivara, Rohini; Chen, Wenlong C; Mensah, James E; Agalliu, Ilir; Berndt, Sonja I; Shelley, John P; Schaffer, Kerry; Machiela, Mitchell J; Freedman, Neal D; Huang, Wen-Yi; Li, Shengchao A; Goodman, Phyllis J; Till, Cathee; Thompson, Ian; Lilja, Hans; Van Den Eeden, Stephen K; Chanock, Stephen J; Mosley, Jonathan D; Conti, David V; Haiman, Christopher A; Justice, Amy C; Kachuri, Linda; Witte, John S
Source
EpiHealth: Epidemiology for Health.
Subject
Language
English
Abstract
We conducted a multi-ancestry genome-wide association study of prostate-specific antigen (PSA) levels in 296,754 men (211,342 European ancestry; 58,236 African ancestry; 23,546 Hispanic/Latino; 3,630 Asian ancestry; 96.5% of participants were from the Million Veteran Program). We identified 318 independent genome-wide significant (p≤5e-8) variants, 184 of which were novel. Most demonstrated evidence of replication in an independent cohort (n=95,768). Meta-analyzing discovery and replication (n=392,522) identified 447 variants, of which a further 111 were novel. Out-of-sample variance in PSA explained by our new polygenic risk score reached 16.9% (95% CI=16.1%-17.8%) in European ancestry, 9.5% (95% CI=7.0%-12.2%) in African ancestry, 18.6% (95% CI=15.8%-21.4%) in Hispanic/Latino, and 15.3% (95% CI=12.7%-18.1%) in Asian ancestry, and lower for higher age. Our study highlights how including proportionally more participants from underrepresented populations improves genetic prediction of PSA levels, with potential to personalize prostate cancer screening.